Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Clinical development of HER3-targeting monoclonal antibodies: Perils and progress.

Jacob W, James I, Hasmann M, Weisser M.

Cancer Treat Rev. 2018 Jul;68:111-123. doi: 10.1016/j.ctrv.2018.06.011. Epub 2018 Jun 18. Review.

PMID:
29944978
2.

Mechanistic Investigations of Diarrhea Toxicity Induced by Anti-HER2/3 Combination Therapy.

Moisan A, Michielin F, Jacob W, Kronenberg S, Wilson S, Avignon B, Gérard R, Benmansour F, McIntyre C, Meneses-Lorente G, Hasmann M, Schneeweiss A, Weisser M, Adessi C.

Mol Cancer Ther. 2018 Jul;17(7):1464-1474. doi: 10.1158/1535-7163.MCT-17-1268. Epub 2018 Apr 13.

PMID:
29654069
3.

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.

Schneeweiss A, Park-Simon TW, Albanell J, Lassen U, Cortés J, Dieras V, May M, Schindler C, Marmé F, Cejalvo JM, Martinez-Garcia M, Gonzalez I, Lopez-Martin J, Welt A, Levy C, Joly F, Michielin F, Jacob W, Adessi C, Moisan A, Meneses-Lorente G, Racek T, James I, Ceppi M, Hasmann M, Weisser M, Cervantes A.

Invest New Drugs. 2018 Oct;36(5):848-859. doi: 10.1007/s10637-018-0562-4. Epub 2018 Jan 19.

PMID:
29349598
4.

Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer.

Collins D, Jacob W, Cejalvo JM, Ceppi M, James I, Hasmann M, Crown J, Cervantes A, Weisser M, Bossenmaier B.

PLoS One. 2017 May 11;12(5):e0177331. doi: 10.1371/journal.pone.0177331. eCollection 2017.

5.

Fit-for purpose use of mouse models to improve predictivity of cancer therapeutics evaluation.

Wartha K, Herting F, Hasmann M.

Pharmacol Ther. 2014 Jun;142(3):351-61. doi: 10.1016/j.pharmthera.2014.01.001. Epub 2014 Jan 8. Review.

PMID:
24412280
6.

Present and future breast cancer management--bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry.

Bartsch R, Frings S, Marty M, Awada A, Berghoff AS, Conte P, Dickin S, Enzmann H, Gnant M, Hasmann M, Hendriks HR, Llombart A, Massacesi C, von Minckwitz G, Penault-Llorca F, Scaltriti M, Yarden Y, Zwierzina H, Zielinski CC; Biotherapy Development Association (BDA).

Ann Oncol. 2014 Apr;25(4):773-80. doi: 10.1093/annonc/mdt531. Epub 2013 Dec 18.

PMID:
24351401
7.

Detection of truncated HER2 forms in formalin-fixed, paraffin-embedded breast cancer tissue captures heterogeneity and is not affected by HER2-targeted therapy.

Krüger JM, Thomas M, Korn R, Dietmann G, Rutz C, Brockhoff G, Specht K, Hasmann M, Feuerhake F.

Am J Pathol. 2013 Aug;183(2):336-43. doi: 10.1016/j.ajpath.2013.04.010. Epub 2013 May 29.

PMID:
23727348
8.

Pertuzumab counteracts the inhibitory effect of ErbB2 on degradation of ErbB3.

Sak MM, Szymanska M, Bertelsen V, Hasmann M, Madshus IH, Stang E.

Carcinogenesis. 2013 Sep;34(9):2031-8. doi: 10.1093/carcin/bgt173. Epub 2013 May 22.

PMID:
23698633
9.

Molecular determinants of trastuzumab efficacy: What is their clinical relevance?

De P, Hasmann M, Leyland-Jones B.

Cancer Treat Rev. 2013 Dec;39(8):925-34. doi: 10.1016/j.ctrv.2013.02.006. Epub 2013 Apr 3. Review.

PMID:
23562214
10.

Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab.

Mamidi S, Cinci M, Hasmann M, Fehring V, Kirschfink M.

Mol Oncol. 2013 Jun;7(3):580-94. doi: 10.1016/j.molonc.2013.02.011. Epub 2013 Feb 20.

11.

Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer.

Sims AH, Zweemer AJ, Nagumo Y, Faratian D, Muir M, Dodds M, Um I, Kay C, Hasmann M, Harrison DJ, Langdon SP.

Br J Cancer. 2012 May 22;106(11):1779-89. doi: 10.1038/bjc.2012.176. Epub 2012 May 1.

12.

Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with Trastuzumab.

Hughes JB, Rødland MS, Hasmann M, Madshus IH, Stang E.

Pharmaceuticals (Basel). 2012 Jun 28;5(7):674-89. doi: 10.3390/ph5070674.

13.

Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs.

Henjes F, Bender C, von der Heyde S, Braun L, Mannsperger HA, Schmidt C, Wiemann S, Hasmann M, Aulmann S, Beissbarth T, Korf U.

Oncogenesis. 2012 Jul 2;1:e16. doi: 10.1038/oncsis.2012.16.

14.

Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies.

Faratian D, Zweemer AJ, Nagumo Y, Sims AH, Muir M, Dodds M, Mullen P, Um I, Kay C, Hasmann M, Harrison DJ, Langdon SP.

Clin Cancer Res. 2011 Jul 1;17(13):4451-61. doi: 10.1158/1078-0432.CCR-10-2461. Epub 2011 May 13.

15.

Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.

Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M.

Cancer Res. 2009 Dec 15;69(24):9330-6. doi: 10.1158/0008-5472.CAN-08-4597.

16.

Modulation of HER3 is a marker of dynamic cell signaling in ovarian cancer: implications for pertuzumab sensitivity.

Nagumo Y, Faratian D, Mullen P, Harrison DJ, Hasmann M, Langdon SP.

Mol Cancer Res. 2009 Sep;7(9):1563-71. doi: 10.1158/1541-7786.MCR-09-0101. Epub 2009 Sep 8.

17.

Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerization.

Hughes JB, Berger C, Rødland MS, Hasmann M, Stang E, Madshus IH.

Mol Cancer Ther. 2009 Jul;8(7):1885-92. doi: 10.1158/1535-7163.MCT-09-0291. Epub 2009 Jul 7.

18.

Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo.

Pohl M, Stricker I, Schoeneck A, Schulmann K, Klein-Scory S, Schwarte-Waldhoff I, Hasmann M, Tannapfel A, Schmiegel W, Reinacher-Schick A.

J Cancer Res Clin Oncol. 2009 Oct;135(10):1377-86. doi: 10.1007/s00432-009-0579-3. Epub 2009 Apr 2.

PMID:
19340455
19.

Flow cytometric FRET analysis of erbB receptor interaction on a cell-by-cell basis.

Diermeier-Daucher S, Hasmann M, Brockhoff G.

Ann N Y Acad Sci. 2008;1130:280-6. doi: 10.1196/annals.1430.003.

PMID:
18596360
20.

Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling.

Mullen P, Cameron DA, Hasmann M, Smyth JF, Langdon SP.

Mol Cancer Ther. 2007 Jan;6(1):93-100.

21.
22.

Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents.

Pogrebniak A, Schemainda I, Azzam K, Pelka-Fleischer R, Nüssler V, Hasmann M.

Eur J Med Res. 2006 Aug 30;11(8):313-21.

PMID:
17052966
23.
24.

Metabolic signatures associated with a NAD synthesis inhibitor-induced tumor apoptosis identified by 1H-decoupled-31P magnetic resonance spectroscopy.

Muruganandham M, Alfieri AA, Matei C, Chen Y, Sukenick G, Schemainda I, Hasmann M, Saltz LB, Koutcher JA.

Clin Cancer Res. 2005 May 1;11(9):3503-13.

26.

Poly ADP-ribose polymerase (PARP) inhibitors transiently protect leukemia cells from alkylating agent induced cell death by three different effects.

Pogrebniak A, Schemainda I, Pelka-Fleischer R, Nüssler V, Hasmann M.

Eur J Med Res. 2003 Oct 22;8(10):438-50.

PMID:
14594650
27.

Cytoprotective features of selenazofurin in hematopoietic cells.

Pogrebniak A, Hasmann M, Schemainda I, Pelka-Fleischer R, Nuessler V.

Int J Clin Pharmacol Ther. 2002 Aug;40(8):368-75.

PMID:
12467305
28.
29.

Modulation of apoptosis by mitochondrial uncouplers: apoptosis-delaying features despite intrinsic cytotoxicity.

Stoetzer OJ, Pogrebniak A, Pelka-Fleischer R, Hasmann M, Hiddemann W, Nuessler V.

Biochem Pharmacol. 2002 Feb 1;63(3):471-83.

PMID:
11853698
30.

In vitro efficacy of known P-glycoprotein modulators compared to droloxifene E and Z: studies on a human T-cell leukemia cell line and their resistant variants.

Nüssler V, Pelka-Fleisc R, Gieseler F, Hasmann M, Löser R, Gullis E, Stötzer O, Zwierzina H, Wilmanns W.

Leuk Lymphoma. 1998 Nov;31(5-6):589-97.

PMID:
9922050
31.

Intracellular localization, vesicular accumulation and kinetics of daunorubicin in sensitive and multidrug-resistant gastric carcinoma EPG85-257 cells.

Seidel A, Hasmann M, Löser R, Bunge A, Schaefer B, Herzig I, Steidtmann K, Dietel M.

Virchows Arch. 1995;426(3):249-56.

PMID:
7773504
32.

Preclinical data for Droloxifene.

Hasmann M, Rattel B, Löser R.

Cancer Lett. 1994 Sep 15;84(2):101-16. Review.

PMID:
8076367
33.

Inhibition of growth-factor-activated proliferation by anti-estrogens and effects on early gene expression of MCF-7 cells.

Wosikowski K, Küng W, Hasmann M, Löser R, Eppenberger U.

Int J Cancer. 1993 Jan 21;53(2):290-7.

PMID:
8425767
34.

Flow cytometric analysis of virus-infected cells and its potential use for screening antiviral agents.

Steele-Mortimer OA, Meier-Ewert H, Löser R, Hasmann MJ.

J Virol Methods. 1990 Mar;27(3):241-52.

PMID:
1691199
35.

Membrane potential differences between adriamycin-sensitive and -resistant cells as measured by flow cytometry.

Hasmann M, Valet GK, Tapiero H, Trevorrow K, Lampidis T.

Biochem Pharmacol. 1989 Jan 15;38(2):305-12.

PMID:
2914014
36.

Acetyl-coenzyme A: arylamine N-acetyltransferases in microorganisms: screening and isolation of an enzyme from Bacillus cereus.

Hasmann MJ, Seidl PH, Engelhardt G, Schleifer KH.

Arch Microbiol. 1986 Dec;146(3):275-9.

PMID:
3103579

Supplemental Content

Loading ...
Support Center